• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 50 10 February 2023 - UK Health Security Agency

Mary Wilson

Well-known member
10 February 2023

Summary


This report has been published to share the detailed variant surveillance analyses which contribute to the variant risk assessments and designation of new SARS-CoV-2 variants. This specialist technical briefing contains early data and analysis on emerging variants and findings have a high level of uncertainty. Unless stated otherwise, this technical briefing uses a data cut- off of 6 February 2023 to allow time for analyses.

Interpreting variant data

The current testing policy needs to be considered when interpreting all variant data; the targeting of testing at specific groups is likely to delay the detection and characterisation of variants. Whilst there are substantial numbers of genomes still being generated, the demographic composition of the cases sequenced is different from total cases in the population with a greater representation of older individuals. This may affect variant characterisation.

Situational risk assessment
Growth advantage


XBB.1.5 and CH.1.1 (and associated sublineages) continue to show growth advantage in England in all models. It is likely that the growth of both CH.1.1. and XBB.1.5 are contributing to the current increase in COVID-19 incidence and that they will continue to increase overall transmission as they become more prevalent. ...

https://assets.publishing.service.g...nt-technical-briefing-50-10-february-2023.pdf
 
Back
Top